• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    NRX Pharmaceuticals, Inc. - Common Stock (NQ:NRXP)

    2.995 +0.005 (+0.17%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Sep 25, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 13,857
    Open 2.995
    Bid (Size) 2.950 (1,500)
    Ask (Size) 3.000 (5,100)
    Prev. Close 2.990
    Today's Range 2.995 - 2.995
    52wk Range 1.620 - 5.055
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    NRx Pharmaceuticals (Nasdaq: NRXP) Reports Update from the FDA Revising Previous Major Amendment to a Minor Amendment for Preservative-free Ketamine
    From NRx Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    First Interventional Psychiatry Use of FDA-Cleared Zeta TMS AI Driven Robotic System in Treatment of Suicidal Bipolar Depression by NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
    Via Get News
    Topics Artificial Intelligence

    Performance

    YTD
    +14.3%
    +14.3%
    1 Month
    -15.6%
    -15.6%
    3 Month
    -25.1%
    -25.1%
    6 Month
    +43.3%
    +43.3%
    1 Year
    -7.8%
    -7.8%

    More News

    Read More
    News headline image
    GeNeuro, Inc., an NRx Company (Nasdaq:NRXP) is awarded European Patent Rights for GNK-301, a novel drug candidate to treat Amyotrophic Lateral Sclerosis (ALS)
    From NRx Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Begins Training and Deployment of Zeta Surgical's FDA-Cleared Robotic TMS System
    From NRx Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    NRx Pharmaceuticals to Participate in Upcoming Investor Conferences
    From NRx Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    FDA First Cycle Review of Preservative-Free Ketamine ANDA with No Drug Related Major Deficiencies Noted for Suicidal Bipolar Depression Treatment from NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
    Via Get News
    News headline image
    NRX Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript ↗
    Via Benzinga
    Topics Earnings
    News headline image
    NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET
    From NRx Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    NRx Pharmaceuticals Nears FDA Decision on Preservative-Free Ketamine After Review Clears Hurdles ↗
    Via MarketBeat
    News headline image
    NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans
    From NRx Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    FDA Completes First-Cycle Review of Preservative-Free Ketamine ANDA with No Drug Related Major Deficiencies; Final Packaging Certification Requested for Approval
    From NRx Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    First Patients Treated via FDA-Cleared Transcranial Magnetic Stimulation, Plus FDA Grant on D-Cycloserine-Based Drug for Depression: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
    Via Get News
    Topics Government
    News headline image
    New to The Street Announces Broadcast of Show #759 on Bloomberg Television Across the U.S., MENA and Latin America tonight 630pm est.
    From New to The Street
    Via ACCESS Newswire
    News headline image
    NRx Pharmaceuticals Responds to Recent Public Statements Regarding Kadima Dispute
    From NRx Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Treats First Patients Using Zeta Surgical's FDA-Cleared Zeta TMS Navigation System
    From NRx Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    NRx Pharmaceuticals Announces FDA Grant of Expanded Access Protocol for Use of D-Cycloserine-based NRX-101 for Augmentation of Transcranial Magnetic Stimulation in the Treatment of Depression
    From NRx Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    New to The Street broadcasts show #758 TODAY AT 6:30 PM ET on BLOOMBERG TELEVISION ACROSS THE UNITED STATES, LATIN AMERICA, AND MENA
    From New to The Street
    Via ACCESS Newswire
    News headline image
    NRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology.
    From NRx Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    NRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters’ Option
    From NRx Pharmaceuticals, Inc.
    Via GlobeNewswire
    These stocks are moving in today's pre-market session ↗
    Via Chartmill
    News headline image
    NRx Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock
    From NRx Pharmaceuticals, Inc.
    Via GlobeNewswire
    What's going on in today's after hours session ↗
    Via Chartmill
    News headline image
    NRx Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
    From NRx Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    NRx Pharmaceuticals (Nasdaq: NRXP) Strategic Partner Emobot Presents Late-Breaking Clinical Validation of the EMOCARE Depression Thermometer at ASCP 2026
    From NRx Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    First Commercial Deployment of FDA-Cleared Transcranial Magnetic Stimulation (TMS) for Major Depressive Disorder and Other Neurological Conditions: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
    Via Get News
    Topics Government

    Frequently Asked Questions

    Is NRX Pharmaceuticals, Inc. - Common Stock publicly traded?
    Yes, NRX Pharmaceuticals, Inc. - Common Stock is publicly traded.
    What exchange does NRX Pharmaceuticals, Inc. - Common Stock trade on?
    NRX Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for NRX Pharmaceuticals, Inc. - Common Stock?
    The ticker symbol for NRX Pharmaceuticals, Inc. - Common Stock is NRXP on the Nasdaq Stock Market
    What is the current price of NRX Pharmaceuticals, Inc. - Common Stock?
    The current price of NRX Pharmaceuticals, Inc. - Common Stock is 2.995
    When was NRX Pharmaceuticals, Inc. - Common Stock last traded?
    The last trade of NRX Pharmaceuticals, Inc. - Common Stock was at 09/25/26 04:00 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.